Top

Gepubliceerd in:

01-10-2014 | Hormonale en reproductieve factoren in de ontwikkeling van blaaskanker

Hormonale en reproductieve factoren in de ontwikkeling van blaaskanker

Auteurs: drs. L. Egbers, dr. ir. S.H. Vermeulen, prof. dr. L.A.L.M. Kiemeney, dr. G.W. Verhaegh

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 6/2014

Samenvatting

Bij mannen wordt drie tot vier keer vaker blaaskanker vastgesteld dan bij vrouwen. Historische verschillen in rookgedrag en beroepsblootstelling verklaren de hogere incidentie bij mannen niet geheel. Er zijn aanwijzingen voor hormonale factoren in de etiologie van blaaskanker. In-vitrostudies en diermodellen suggereren dat de androgeenreceptor een essentiële rol speelt bij de carcinogenese en progressie van blaaskanker. Soortgelijke studies naar de invloed van oestrogenen en de oestrogeenreceptor leiden tot tegenstrijdige resultaten en naar de rol van progesteron en de progesteronreceptor is nog weinig onderzoek gedaan. Epidemiologische studies naar reproductieve en hormonale factoren laten vaak inconsistente resultaten zien. Echter, grote patiëntcontrole- en cohortonderzoeken laten consistent zien dat pariteit het risico op blaaskanker verlaagt. Hormoontherapie met oestrogenen in combinatie met progesteron lijkt het risico ook te verlagen. Verdere onderzoeken zijn nodig om te bepalen hoe geslachtshormonen de tumorontwikkeling in het urotheel kunnen beïnvloeden.

vorige artikel Antibiotische behandeling van infectieuze complicaties en urosepsis na een transrectale prostaatbiopsie of goudmarkerimplantatie

volgende artikel Laparoscopische en retroperitoneoscopische adrenalectomie voor bijnierziekten: vergelijking van perioperatieve uitkomsten

Ferlay J, Shin HR, Bray F, Forman D, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef

Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45.PubMedCrossRefPubMedCentral

Hartge P, Harvey EB, Linehan WM, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990;82:1636–40.PubMedCrossRef

Hemelt M, Yamamoto H, Cheng KK, Zeegers MP. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer. 2009;124:412–9.PubMedCrossRef

Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62:118–25.PubMedCrossRef

Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000;55:876–80.PubMedCrossRef

Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol. 2012;42:569–77.PubMedCrossRef

Mir C, Shariat SF, Kwast TH van der, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011;108:24–30.PubMedCrossRef

Gakis G, Stenzl A. Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol.2013;31:1059–64.PubMedCrossRef

10.

Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer. 1972;8:587–94.PubMedCrossRef

11.

Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558–68.PubMedCrossRef

12.

Okajima E, Hiramatsu T, Iriya K, et al. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res. 1975;3:73–9.PubMedCrossRef

13.

Reid LM, Leav I, Kwan PW, et al. Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice. Cancer Res. 1984;44:4560–73.PubMed

14.

Imada S, Akaza H, Ami Y, Koiso K, et al. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol. 1997;31:360–4.PubMed

15.

Pour PM, Stepan K. Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl)amine. Cancer Res. 1987;47:5699–706.PubMed

16.

Hsu JW, Hsu I, Xu D, et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol. 2013;182:1811–20.PubMedCrossRefPubMedCentral

17.

Johnson AM, O’Connell MJ, Miyamoto H, et al. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol. 2008;8:7.PubMedCrossRefPubMedCentral

18.

Wu JT, Han BM, Yu SQ, et al. Androgen receptor is a potential therapeutic target for bladder cancer. Urology. 2010;75:820–7.PubMedCrossRef

19.

Imaoka S, Yoneda Y, Sugimoto T, et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett. 2001;166:119–23.PubMedCrossRef

20.

Izumi K, Zheng Y, Hsu JW, et al. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog. 2013;52:94–102.PubMedCrossRef

21.

Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006;106:2610–6.PubMedCrossRef

22.

Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol. 2009;56:1093–5.PubMedCrossRef

23.

Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109:1716–26.PubMedCrossRef

24.

Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011;29:43–51.PubMedCrossRef

25.

Han B, Cui D, Jing Y, et al. Estrogen receptor beta (ERbeta) is a novel prognostic marker of recurrence survival in non-muscleinvasive bladder cancer potentially by inhibiting cadherin switch. World J Urol. 2012;30:861–7.PubMedCrossRef

26.

Shirai T, Tsuda H, Ogiso T, et al. Organ specific modifying potential of ethinyl estradiol on carcinogenesis initiated with different carcinogens. Carcinogenesis. 1987;8:115–9.PubMedCrossRef

27.

Teng J, Wang ZY, Jarrard DF, Bjorling DE. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocr Relat Cancer. 2008;15:351–64.PubMedCrossRefPubMedCentral

28.

George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. Transl Oncol. 2013;6:244–55.PubMedCrossRefPubMedCentral

29.

Hsu I, Chuang KL, Slavin S, et al. Suppression of ERbeta signaling via ERbeta knockout or ERbeta antagonist protects against bladder cancer development. Carcinogenesis. 2014;35:651–61.PubMedCrossRef

30.

Hsu CH, Chen J, Wu CY, et al. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 2001;21:711–5.PubMed

31.

Noronha RF, Rao BR. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology. 1986;28:401–3.PubMedCrossRef

32.

Daugherty SE, Lacey JV, Jr., Pfeiffer RM, et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer. 2013;133:462–72.PubMedCrossRefPubMedCentral

33.

Davis-Dao CA, Henderson KD, Sullivan-Halley J, et al. Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev. 2011;20:1156–70.PubMedCrossRefPubMedCentral

34.

Dietrich K, Demidenko E, Schned A, et al. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer. 2011;47:592–9.PubMedCrossRefPubMedCentral

35.

Cantor KP, Lynch CF, Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control. 1992;3:57–62.PubMedCrossRef

36.

Kabat GC, Kim MY, Luo J, et al. Menstrual and reproductive factors and exogenous hormone use and risk of transitional cell bladder cancer in postmenopausal women. Eur J Cancer Prev. 2013;22:409–16.PubMedCrossRef

37.

Wijma J, Weis Potters AE, de Wolf BT, et al. Anatomical and functional changes in the lower urinary tract during pregnancy. BJOG. 2001;108:726–32.PubMed

38.

Pelucchi C, La Vecchia C, Negri E, et al. Smoking and other risk factors for bladder cancer in women. Prev Med. 2002;35:114–20.PubMedCrossRef

39.

Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62:45–51.PubMedCrossRef

40.

La Vecchia C, Negri E, D’Avanzo B, et al. Genital and urinary tract diseases and bladder cancer. Cancer Res. 1991;51:629–31.PubMed

Titel: Hormonale en reproductieve factoren in de ontwikkeling van blaaskanker
Auteurs: drs. L. Egbers
dr. ir. S.H. Vermeulen
prof. dr. L.A.L.M. Kiemeney
dr. G.W. Verhaegh
Publicatiedatum: 01-10-2014
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Urologie / Uitgave 6/2014
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI: https://doi.org/10.1007/s13629-014-0070-z

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2014

Antibiotische behandeling van infectieuze complicaties en urosepsis na een transrectale prostaatbiopsie of goudmarkerimplantatie

Laparoscopische en retroperitoneoscopische adrenalectomie voor bijnierziekten: vergelijking van perioperatieve uitkomsten

Case report. Een GIST-tumor gecombineerd met een niercelcarcinoom en oncocytoom

Editorial